FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-028								
Estimated average I	nurden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Enyedy Mark J					2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Ellyedy Midik J															X	Direc	tor		10% C	Owner	
(Last) (First) (Middle) 24 CONCORD SQUARE						3. Date of Earliest Transaction (Month/Day/Year) 02/24/2020									X	belov	,	Other (specify below) utive Officer			
(Street) BOSTON MA 02118				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person							
(City)	(St	ate)	(Zip)													Form	Form filed by More than One Reporting Person				
		Tab	le I - No	n-Deriv	ative	Sec	curitie	s Acc	quired,	Dis	posed o	f, o	r Ben	eficia	ally (Dwne	ed				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					r) Ei	A. Deemed Execution Date, f any Month/Day/Year)		Transaction Disposed Of Code (Instr.			ies Acquired (A) Of (D) (Instr. 3, 4			and 5) Sec Bei Ow		ount of ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										v	Amount		(A) or (D)	Price		Transa	Reported Fransaction(s) Instr. 3 and 4)			(111501.4)	
Common Stock 02/2				02/24/	′2020				S		55,222 ⁽²⁾		D	\$4.99(1)		433,776		D			
		Ta									sed of, onvertib				y Ov	ned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Exercise (Month/Day/Year) if any (Month/Day/Year) irany		n Date, Day/Year) -		5. Number of Oberivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ative rities ired psed	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares			nt er		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Own Forn Dire or In (I) (II	ership 1: ct (D) direct 1str. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- 1. Weighted average price of shares sold.
- 2. The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person.

/s/ Craig Barrows, attorney in fact

02/25/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.